StageZero Life Sciences has a quick ratio of 0.02. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for StageZero Life Sciences's Quick Ratio or its related term are showing as below:
TSXV:SZLS.H's Quick Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.67 * Ranked among companies with meaningful Quick Ratio only.
StageZero Life Sciences (TSXV:SZLS.H) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
StageZero Life Sciences Quick Ratio Related Terms
StageZero Life Sciences Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:SZLS.H vs IDTA, TTOO, NSTM: Quick Ratio Comparison
For the Diagnostics & Research subindustry, StageZero Life Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StageZero Life Sciences Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where StageZero Life Sciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
StageZero Life Sciences's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StageZero Life Sciences (TSXV:SZLS.H) has a Quick Ratio of 0.02 as of Sep. 2024. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' Quick Ratio too high?
StageZero Life Sciences' current Quick Ratio is 0.02. The Medical Diagnostics & Research industry median Quick Ratio is 1.67. StageZero Life Sciences' value of 0.02 is 98.8% below this industry median. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Quick Ratio compare to IDTA and TTOO?
StageZero Life Sciences' Quick Ratio of 0.02 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Quick Ratio is 1.67. StageZero Life Sciences' value of 0.02 is 98.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.67, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StageZero Life Sciences's current Quick Ratio of 0.02 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on StageZero Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StageZero Life Sciences's current Quick Ratio is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (TSXV:SZLS.H) has a current Quick Ratio of 0.02. The current Quick Ratio is 0.02 and 98.8% below the Medical Diagnostics & Research industry median of 1.67. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For StageZero Life Sciences (TSXV:SZLS.H), the current Quick Ratio is 0.02 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score
Get the complete analysis for TSXV:SZLS.H
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:SZLS.H has been successfully added to your 
